Bruker (NASDAQ:BRKR) Share Price Passes Above 200 Day Moving Average – Should You Sell?

Shares of Bruker Corporation (NASDAQ:BRKR) crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $44.59 and traded as high as $61.21. Bruker shares last traded at $59.71, with a volume of 1,988,242 shares trading hands.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on BRKR shares. Barclays boosted their price target on Bruker from $53.00 to $60.00 and gave the stock an “overweight” rating in a report on Wednesday, June 24th. UBS Group set a $60.00 target price on shares of Bruker in a research report on Wednesday, June 24th. Weiss Ratings raised shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, June 3rd. Guggenheim upped their price target on shares of Bruker from $50.00 to $70.00 and gave the company a “buy” rating in a research report on Monday. Finally, Stifel Nicolaus set a $45.00 price target on shares of Bruker in a research report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bruker presently has a consensus rating of “Hold” and a consensus target price of $54.54.

Bruker Price Performance

The company has a fifty day simple moving average of $48.91 and a 200 day simple moving average of $44.59. The stock has a market capitalization of $9.09 billion, a price-to-earnings ratio of -248.79, a P/E/G ratio of 1.95 and a beta of 1.30. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.72 and a current ratio of 1.55.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.08. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The company had revenue of $823.40 million during the quarter, compared to analysts’ expectations of $795.62 million. During the same quarter in the prior year, the firm posted $0.47 earnings per share. The business’s quarterly revenue was up 2.7% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities research analysts forecast that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 7th. Shareholders of record on Monday, June 22nd will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Monday, June 22nd. Bruker’s dividend payout ratio is currently -83.33%.

Insider Transactions at Bruker

In other Bruker news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total transaction of $79,800.00. Following the completion of the transaction, the vice president owned 128,443 shares in the company, valued at approximately $5,124,875.70. This trade represents a 1.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 27.20% of the company’s stock.

Hedge Funds Weigh In On Bruker

A number of hedge funds have recently bought and sold shares of BRKR. Orbis Allan Gray Ltd bought a new stake in Bruker during the second quarter valued at $192,735,000. Price T Rowe Associates Inc. MD raised its position in shares of Bruker by 2,963.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company’s stock worth $111,488,000 after acquiring an additional 2,289,269 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Bruker by 125.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock worth $137,065,000 after acquiring an additional 1,850,215 shares in the last quarter. Franklin Resources Inc. lifted its stake in shares of Bruker by 317.7% in the 4th quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock valued at $108,796,000 after purchasing an additional 1,756,460 shares during the period. Finally, Millennium Management LLC lifted its stake in shares of Bruker by 222.6% in the 4th quarter. Millennium Management LLC now owns 1,839,587 shares of the medical research company’s stock valued at $86,663,000 after purchasing an additional 1,269,316 shares during the period. Institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.